Smoldering Myeloma
Links shared publicly online about this topic
Paradigm Shift: MGUS, Smoldering Myeloma, And Multiple Myeloma Are All One Disease - The Myeloma Beacon
myelomabeacon.com — “Until 2009, it was generally accepted that monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma, and multiple myeloma were ...” View full resource at myelomabeacon.com
Most Recently Shared on November 13, 2010 at 4:35 pm By:
Physician Assistants Health News Feed
Physician Assistants expertly do bone marrow biopsies: http://bit.ly/cyzF4i Multiple myeloma
The progression from MGUS to smoldering myeloma an... [Clin Cancer Res. 2011] - PubMed result
ncbi.nlm.nih.gov — “PubMed is a service of the U.S. National Library of Medicine that includes over 19 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on February 18, 2011 at 11:50 pm By:
Robert Z. Orlowski Physician, Doctor, and Internist
Progression from MGUS->myeloma->symptomatic myeloma associated with more genetic abnormalities in plasma cells (http://bit.ly/go6R8M).
Lenalidomide Improves Outcomes in Asymptomatic High-Risk Smoldering and Newly Diagnosed Myeloma
onclive.com — “Continuous treatment with lenalidomide given early prolonged the time to progression, compared with no treatment in patients with high-risk, asymptomatic, smoldering, multiple myeloma.” View full resource at onclive.com
Most Recently Shared on March 23, 2012 at 8:48 pm By:
Early, continuous treatment with Revlimid prolonged the time to progression in patients with smoldering #myeloma http://t.co/2C5Cn060
Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM
news-medical.net — “Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that updated data evaluating continuous treatment with REVLIMID (lenalidomide) in patients with high-risk asymptomatic smoldering multiple myeloma were presented at the 53rd Annual Meeting of the American Society of Hematology.” View full resource at news-medical.net
Most Recently Shared on December 14, 2011 at 3:21 pm By:
Prostate Cancer: Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM: C... http://t.co/m4attbxF
Paper: Smoldering Multiple Myeloma (SMM) at High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) as Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No
ash.confex.com — “Paper: Smoldering Multiple Myeloma (SMM) at High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) as Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment” View full resource at ash.confex.com
Most Recently Shared on November 28, 2010 at 5:44 pm By:
Robert Z. Orlowski Physician, Doctor, and Internist
Revlimid + Dex shortened the time to progression of patients with smoldering myeloma to symptomatic disease (http://bit.ly/eEtD7T).
Understanding a Multiple Myeloma Diagnosis - Patient Power
patientpower.info — “What is myeloma? What does a myeloma diagnosis mean for you? In this video, Dr. Noopur Raje explains myeloma’s effect on the body, blood and bones. Dr. Bill Bensinger joins Dr. Raje to explore the different types of myeloma—including MGUS and smoldering myeloma—and discusses developing research into whether or not early treatment at an asymptomatic phase of the disease is beneficial.” View full resource at patientpower.info
Most Recently Shared on February 29, 2012 at 4:24 pm By:
Understanding a Multiple Myeloma Diagnosis - Patient Power - http://t.co/LdjSitJP
Pamidronate versus observation in asymptomatic mye... [Leuk Lymphoma. 2011] - PubMed result
ncbi.nlm.nih.gov — “PubMed is a service of the U.S. National Library of Medicine that includes over 19 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on February 10, 2011 at 3:18 pm By:
Robert Z. Orlowski Physician, Doctor, and Internist
New study: Pamidronate reduces skeletal events, but doesn't delay progression from smoldering to symptomatic myeloma (http://bit.ly/fkdDsf).
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Physician Assistants
- Physician Assistants (P.A.) are licensed health professionals who practice medicine with the supervision of a physician
-
Robert Z. Orlowski
Director of Myeloma Section at M. D. Anderson Cancer Center; Translational researcher who hates myeloma
-
Editor
Editors of Oncology & Biotech News/Oncology Net Guide/OncNurse/Contemporary Oncology, on cancer news from pharma, trials, technology, & more.
Advertisement
